Jump to content

IQVIA

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Ser Amantio di Nicolao (talk | contribs) at 04:38, 29 January 2021 (add authority control). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

"Quintiles" redirects here. For other uses, see Quintile (disambiguation).
IQVIA Holdings, Inc.
Company typePublic
IndustryContract Research Organization
Pharmaceutical Service Consulting
Founded1982; 42 years ago (1982)
HeadquartersDanbury, Connecticut, USA
Durham, North Carolina, USA
Key people
Dennis Gillings, Founder
Ari Bousbib, Chairman and CEO
ProductsSupport services for pharmaceutical, biotech and medical companies and individuals
RevenueIncreaseUS$11.1088 billion (2019)[1]
Increase US$111.33 billion (2017)[1]
Total assetsIncrease US$233.251 billion (2019)[1]
Number of employees
67,000+ [1] (2019)
Websiteiqvia.com

IQVIA, formerly Quintiles and IMS Health, Inc.,[2] is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services. It has a network of more than 58,000 employees in more than 100 countries.[2] As of 2019, IQVIA was reported to be one of the world's largest contract research organizations.[3]

History

In 1982, Dennis Gillings founded and incorporated Quintiles Transnational in North Carolina.[4] Quintiles Transnational established Quintiles Pacific Inc. and Quintiles Ireland Ltd. in 1990.[5] In 1991 Quintiles GmbH was established in Germany and Quintiles Laboratories Ltd. was established in Atlanta, Georgia.[6] In September 1996, Quintiles purchased Innovex Ltd. of Britain for $747.5 million in stock.[7] Quintiles went public in 1997 and completed a successful secondary stock offering.[8]

Over the course of 2016, concluding on October 3, Quintiles underwent a $17.6 billion merger with IMS Health, becoming QuintilesIMS.[9] As a result of the merger, the OneKey worldwide healthcare professionals database developed by Cegedim Relationship Management became part of QuintilesIMS.

In November 2017, the company adopted the new name of IQVIA, and changed its ticker symbol on the NYSE from Q to IQV.[2]

References

  1. ^ a b c d "☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934" (PDF). U.S. Securities and Exchange Commission. Retrieved 29 September 2018.
  2. ^ a b c "QuintilesIMS is now IQVIA". Business Wire. 6 November 2017. Retrieved 6 November 2017.
  3. ^ Melissa Fassbender (9 November 2017). "QuintilesIMS now IQVIA as it aims to 'outpace the inevitable progress of change'". Outsourcing-Pharma.com; William Reed Business Media Ltd. Retrieved 17 December 2017.
  4. ^ Matthew Herper (November 22, 2010). "Money, Math and Medicine". Forbes Magazine. Retrieved July 21, 2011.
  5. ^ "Quintiles Pacific, Inc.: Private Company Information - Businessweek".
  6. ^ "Quintiles Laboratories Limited: Private Company Information - Businessweek".
  7. ^ "Quintiles Transnational Corp". Encyclopedia.com. 2005. {{cite web}}: Unknown parameter |authors= ignored (help)
  8. ^ Olivia Oran (9 May 2013). "Quintiles IPO raises more-than-planned $947 million as stocks rally". Reuters.
  9. ^ Henderson, Jennifer (3 October 2016). "Quintiles, IMS Health complete merger". Triangle Business Journal, American City Business Journals. Retrieved 3 October 2016.
Retrieved from "https://en.wikipedia.org/w/index.php?title=IQVIA&oldid=1003481002"